SRR1486304
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.431
- INTERFERON_ALPHA_RESPONSE+0.322
- TNFA_SIGNALING_VIA_NFKB+0.262
- INTERFERON_GAMMA_RESPONSE+0.259
- IL2_STAT5_SIGNALING+0.253
- PROTEIN_SECRETION+0.248
- ALLOGRAFT_REJECTION+0.225
- FATTY_ACID_METABOLISM+0.220
- INFLAMMATORY_RESPONSE+0.211
- BILE_ACID_METABOLISM+0.208
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.375
- MYC_TARGETS_V2-0.319
- E2F_TARGETS-0.287
- PANCREAS_BETA_CELLS-0.276
- G2M_CHECKPOINT-0.263
- OXIDATIVE_PHOSPHORYLATION-0.226
- KRAS_SIGNALING_DN-0.208
- DNA_REPAIR-0.154
- MYC_TARGETS_V1-0.147
- NOTCH_SIGNALING-0.125
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1333694 | GTEX | — | 0.950 |
| 2 | SRR1488172 | GTEX | — | 0.919 |
| 3 | SRR1346813 | GTEX | — | 0.898 |
| 4 | SRR1413768 | GTEX | — | 0.890 |
| 5 | SRR1429244 | GTEX | — | 0.878 |
| 6 | SRR1340133 | GTEX | — | 0.874 |
| 7 | SRR1402840 | GTEX | — | 0.861 |
| 8 | SRR1092706 | GTEX | — | 0.856 |
| 9 | SRR1085782 | GTEX | — | 0.839 |
| 10 | SRR1323603 | GTEX | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.431 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.322 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.262 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.259 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.253 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.248 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.225 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.211 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.208 | Inavolisib | — uncovered |
| APOPTOSIS | 0.184 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.168 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.167 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.138 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.137 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.095 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.082 | Inavolisib | — uncovered |